Post Marketing Surveillance of Telostop TAB (Telmisartan/Rosuvastatin) for Evaluating the Safety and Efficacy

Post Marketing Surveillance of Telostop TAB (Telmisartan/Rosuvastatin) for Evaluating the Safety and Efficacy

Post-marketing surveillance of Telostop TAB (Telmisartan/Rosuvastatin)

Telostop TAB is fixed-dose combination of telmisartan and rosuvastatin, which was approved in 2015 in the Republic of Korea for the treatment of patients with hypertention and dyslipidemia. A post-marketing surveillance was conducted following the approval to obtain data on the safety and efficacy of Telostop TAB in real-world practice.

Inclusion Criteria:

• The patient who is first prescribed and administered Telostop plus Tab.

Exclusion Criteria:

• The patients who are overreacting to this drug or its components
• The patients to the "Do not administer to the next patient" section of the approved instructions for use